MARKET

MRNA

MRNA

Moderna
NASDAQ

Real-time Quotes | Nasdaq Last Sale

69.26
-0.61
-0.87%
After Hours: 68.81 -0.45 -0.65% 19:59 09/21 EDT
OPEN
68.60
PREV CLOSE
69.87
HIGH
69.48
LOW
65.46
VOLUME
8.22M
TURNOVER
--
52 WEEK HIGH
95.21
52 WEEK LOW
13.53
MARKET CAP
27.33B
P/E (TTM)
-49.5033
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Vaccine Protocols
The number of people infected in the treatment group versus the control group is the most important data point in the entire trial.All these trials have prespecified alerts and stopping criteria if the DSMB sees a given number of adverse events as well.I would expect the companies involved to announce a positive result if they do make any of the interim analysis hurdles.
Seekingalpha · 7h ago
Moderna (MRNA) Stock Still Has Room To Run, Says Analyst
mRNA specialist Moderna (MRNA) is among the leading players in the race to be first to market with a COVID-19 vaccine and the market has been kind in return. Overall, the stock is up 254% year-to-date. According to Needham analyst Alan Carr, the market is not the only space where Moderna is performing
TipRanks · 7h ago
Inovio Defies Market-Wide Weakness: What's Behind The Rally?
Inovio Pharmaceuticals Inc (NASDAQ: INO) shares have been seeing strong momentum ever since hitting a near-term low of $8.78 on Sept. 4.
Benzinga · 11h ago
Medicare coverage of COVID-19 vaccine not there - WSJ
The Wall Street Journal reports that Medicare won't cover the cost of any coronavirus vaccine approved under an FDA Emergency Use Authorization ((EUA)), consistent with current policy of not covering
Seekingalpha · 14h ago
Trump's coronavirus vaccine czar says U.S. could immunize 'most susceptible' Americans by December
The U.S. could also immunize "most of the elderly" and health-care workers in January 2021, Dr. Moncef Slaoui, who is leading the Trump administration's Operation War Speed, said.
CNBC.com · 15h ago
Covid Report: AstraZeneca Now Seen As Lagging In Vaccine Race
Investor's Business Daily · 16h ago
Trump's Pep Talk Raises Vaccine Hopes: 4 Stocks to Watch
Biotech firms and drugmakers across the globe are pumping in millions of dollars to develop a vaccine to wipe out the deadly coronavirus.
Zacks · 18h ago
'Pres. Trump says a #COVID19 vaccine will be available by the end of October. Pressed on which company would be first, Trump says: "Pfizer's doing really well." $PFE Says $JNJ, $MRNA and $AZN are also doing well but will likely be later'
https://twitter.com/kaylatausche/status/1308020937028251655
Benzinga · 18h ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 15 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MRNA stock price target is 92.54 with a high estimate of 134.00 and a low estimate of 41.00.
EPS
Institutional Holdings
Institutions: 538
Institutional Holdings: 217.76M
% Owned: 55.19%
Shares Outstanding: 394.59M
TypeInstitutionsShares
Increased
126
40.03M
New
289
7.76M
Decreased
87
24.26M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.94%
Pharmaceuticals & Medical Research
-2.24%
Key Executives
Non-Executive Chairman/Co-Founder/Independent Director
Noubar Afeyan
President
Stephen Hoge
Chief Executive Officer/Director
Stephane Bancel
Chief Financial Officer
David Meline
Chief Human Resource Officer
Tracey Franklin
Chief Technology Officer
Juan Andres
General Counsel/Secretary
Lori Henderson
Other
Marcello Damiani
Other
Tal Zaks
Other
Ray Jordan
Other
Tal Zvi Zaks
Director
Elizabeth Tallett
Non-Executive Independent Director
Stephen Berenson
Non-Executive Independent Director
Robert Langer
Non-Executive Independent Director
Francois Nader
Non-Executive Independent Director
Israel Ruiz
Non-Executive Independent Director
Paul Sagan
  • Dividends
  • Splits
  • Insider Activity
No Data

Analyst Price Target

The average MRNA stock price target is 92.54 with a high estimate of 134.00 and a low estimate of 41.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About MRNA
Moderna, Inc. is engaged in transformative medicines based on messenger ribonucleic acid (mRNA). It has created a platform to improve the underlying pharmaceutical properties of our mRNA medicines. Its platform consists of three areas: mRNA technologies, delivery technologies, and manufacturing processes. It is pursuing mRNA science to minimize the undesirable activation of the immune system by mRNA and to maximize the potency of mRNA once in the target cells. It has advanced in parallel a diverse development pipeline of 21 programs, of which 10 have entered clinical studies and another three have open INDs. Its therapeutics and vaccine development programs span infectious diseases, oncology, cardiovascular diseases, and rare genetic diseases. It has created six modalities prophylactic vaccines, cancer vaccines, intratumoral immmuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics and systemic intracellular therapeutics.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Moderna Inc stock information, including NASDAQ:MRNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRNA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MRNA stock methods without spending real money on the virtual paper trading platform.